Evidence map›Paper›PMID 42087001›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Switching to dupilumab from other biologic therapies in chronic rhinosinusitis with nasal polyps (CRSWNP): a comparison with biologic-naïve patients.

Daniela Lucidi, Veronica Seccia, Rodolfo Mastrapasqua, Virginia Dallari, Matteo Alicandri-Ciufelli, Ignacio Javier Fernandez, Carlotta Pipolo, Gianluca Fadda, Massimiliano Garzaro, Valeria Dell'Era and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daniela LucidiDIMEC Department, Bologna University, Santa Maria Delle Croci Hospital, Ravenna, Italy. dani.lucidi@gmail.com.ORCID http://orcid.org/0000-0003-3341-5926
Veronica SecciaOtolaryngology, Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.
Rodolfo MastrapasquaENT Department, Rivoli Hospital, Rivoli, ASL TO3, Italy.
Virginia DallariDIMEC Department, Bologna University, Santa Maria Delle Croci Hospital, Ravenna, Italy.
Matteo Alicandri-CiufelliDepartment of Otolaryngology-Head and Neck Surgery, University Hospital of Modena, Modena, Italy.
Ignacio Javier FernandezDIMEC Department, Bologna University, Santa Maria Delle Croci Hospital, Ravenna, Italy.
Carlotta PipoloOtolaryngology Unit, Department of Health Sciences, Santi Paolo e Carlo Hospital, Università Degli Studi di Milano, Milan, Italy.
Gianluca FaddaDepartment of Otolaryngology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043, Italy.
Massimiliano GarzaroDepartment of Otorhinolaryngology, Rhinology Unit, Eastern Piedmont University, Maggiore Hospital, Novara, Italy.
Valeria Dell'EraDepartment of Otorhinolaryngology, Rhinology Unit, Eastern Piedmont University, Maggiore Hospital, Novara, Italy.
Lorenzo CarrieraDepartment of Pulmonology and Sub-Intensive Respiratory Unit, Ospedale Santa Maria della Misericordia, Perugia, Italy.
Ilaria PuxedduImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Francesco MenzellaPulmonology Unit, S. Valentino Hospital, AULSS2 Marca Trevigiana, Montebelluna, TV, Italy.
Valeria GambacortaDepartment of Medicine & Surgery, University of Perugia, Otorhinolaryngology Ospedale Santa Maria della Misericordia Perugia, Perugia, Italy.
Giampietro RicciDepartment of Medicine & Surgery, University of Perugia, Otorhinolaryngology Ospedale Santa Maria della Misericordia Perugia, Perugia, Italy.
Eugenio De CorsoDepartment of Medicine & Surgery, University of Perugia, Otorhinolaryngology Ospedale Santa Maria della Misericordia Perugia, Perugia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeData on the impact of previous biologic treatment on the effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are still limited. This study aimed to compare clinical outcomes of dupilumab in patients previously treated with asthma-targeted biologics who switched to dupilumab due to inadequate disease control, versus biologic-naïve patients.

methodsThis study was designed as a retrospective matched case-control study within the Italian DUPIREAL network, including patients with severe CRSwNP and severe asthma, all treated with dupilumab. Among these, we identified 44 consecutive patients with severe uncontrolled CRSwNP and asthma who initiated dupilumab after asthma-targeted biologics (Group A) and compared them with biologic-naïve CRSwNP and asthma patients receiving dupilumab as their first biologic treatment (Group B, n = 44), matched 1:1 at baseline based on asthma severity (according to GINA classification). Clinical, endoscopic, olfactory, asthma-related, and laboratory parameters were assessed at baseline and during a 24-month follow-up.

resultsBaseline clinical characteristics were comparable between groups. Dupilumab treatment led to a marked and sustained improvement in all the analyzed outcomes in both groups without any significant differences in clinical outcomes at any follow-up timepoint. Among patients who switched to dupilumab, those with well-controlled asthma at baseline did not experience any deterioration in asthma control, whereas patients with uncontrolled asthma showed a significant improvement in asthma control during dupilumab therapy. Although blood eosinophil counts increased more frequently in the switching group from 12 months onward, no negative impact on clinical outcomes, safety, or treatment discontinuation was observed, with comparable adverse event rates between groups.

conclusionsDupilumab was equally effective in patients with CRSwNP and asthma regardless of previous biologic treatment. Switching from other asthma-targeted biologics did not lead to loss of asthma control, and switchers more frequently developed eosinophilia without an associated increase in adverse events or treatment discontinuation.

Indexed as

Antibodies, Monoclonal, HumanizedAsthmaDrug SubstitutionNasal PolypsRhinosinusitisSinusitisAdultCase-Control StudiesChronic DiseaseFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizeddupilumabBiological therapyChronic rhinosinusitis with nasal polypsCRSwNPDupilumabMonoclonal antibodies

Identifiers

PMID42087001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.